Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • APX3330
    • APX2009
    • Phentolamine Ophthalmic Solution 0.75%
    • Scientific Posters and Publications
  • Clinical Trials
    • Overview
    • VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia Enrolling
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Completed
    • MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects Completed
    • MIRA-3 Completed
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Completed
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Completed
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

Read Press Release

Ocuphire in the News

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events
  • Ocuphire in the News
Presbyopia Physician November 2021

Presbyopia Physician November 2021

Nov 15, 2021

Highlights from American Academy of Ophthalmology Conference 2021

Nov 13, 2021
 With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

With Vuity Approval, AbbVie Continues Stepping Into Eye Care- AbbVie Could Create Market For Other Presbyopia Players

Nov 3, 2021

Investigative Oral Retina Drug APX3330 Shows Favorable Safety, Tolerability

Oct 9, 2021

Getting the Drop on Presbyopia: A look at the pharmacologic solutions in the treatment pipeline

Sep 1, 2021

Ocuphire Recognized in Small Business Dealmakers Awards Honors

May 27, 2021

Presbyopia – A Review of Current Treatment Options and Emerging Therapies

May 24, 2021

Indiana CTSI Project Development Team support leads to phase 2 study, ZETA-1

May 17, 2021

Building Value for Pipeline Assets with Mina Sooch

Apr 14, 2021

VIDEO: Drop accelerates mydriasis reversal, reduces dim light disturbances

Apr 13, 2021
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
Ocuphire Pharma, Inc.
© Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use